Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CSBR Champions Oncology (CSBR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSustainabilityTrends About Champions Oncology Stock (NASDAQ:CSBR) 30 days 90 days 365 days Advanced Chart Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get Champions Oncology alerts:Sign Up Key Stats Today's Range$4.26▼$4.6450-Day Range$9.11▼$10.9652-Week Range$7.19▼$14.68Volume22,552 shsAverage Volume11,666 shsMarket Capitalization$58.44 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingBuy Company OverviewChampions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.Read More… This Bull Market Indicator called NVDA at $116 (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Champions Oncology Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks83rd Percentile Overall ScoreCSBR MarketRank™: Champions Oncology scored higher than 83% of companies evaluated by MarketBeat, and ranked 186th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingChampions Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageChampions Oncology has only been the subject of 1 research reports in the past 90 days.Read more about Champions Oncology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Champions Oncology is -16.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Champions Oncology is -16.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Champions Oncology's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.22% of the float of Champions Oncology has been sold short.Short Interest Ratio / Days to CoverChampions Oncology has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Champions Oncology has recently decreased by 5.30%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldChampions Oncology does not currently pay a dividend.Dividend GrowthChampions Oncology does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.81 Percentage of Shares Shorted3.22% of the float of Champions Oncology has been sold short.Short Interest Ratio / Days to CoverChampions Oncology has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Champions Oncology has recently decreased by 5.30%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Champions Oncology this week, compared to 8 articles on an average week. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Champions Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders46.98% of the stock of Champions Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.30% of the stock of Champions Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Champions Oncology's insider trading history. Receive CSBR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Champions Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address CSBR Stock News HeadlinesBoys cross country: 'Insane, absurd' performance as CBA, Joe Barrett win Meet of ChampionsNovember 17, 2024 | msn.comChampions League: Guardiola names team he wants Man City not to faceOctober 14, 2024 | msn.com2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.November 21, 2024 | Darwin (Ad)Pep Guardiola names team he's desperate for Man City to avoid in Champions LeagueOctober 14, 2024 | mirror.co.ukPlayers Who Have Won the Champions League, Ballon d'Or & World CupOctober 13, 2024 | msn.comYoung Avengers vs. New Champions: Scarlet Witch's Children Face Off Against Her New Protege In A Battle Of Marvel's Next GenerationOctober 13, 2024 | msn.comChampions Oncology President Brady Davis Dies >CSBROctober 4, 2024 | marketwatch.comChampions Oncology (NASDAQ:CSBR) Stock, Short Interest ReportOctober 4, 2024 | benzinga.comSee More Headlines CSBR Stock Analysis - Frequently Asked Questions How were Champions Oncology's earnings last quarter? Champions Oncology, Inc. (NASDAQ:CSBR) announced its earnings results on Wednesday, September, 11th. The biotechnology company reported $0.09 EPS for the quarter. The biotechnology company had revenue of $14.06 million for the quarter. Who are Champions Oncology's major shareholders? Champions Oncology's top institutional shareholders include HighTower Advisors LLC (0.29%). Insiders that own company stock include Ronnie Morris and Daniel Newman Mendelson. View institutional ownership trends. What other stocks do shareholders of Champions Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Champions Oncology investors own include Intel (INTC), Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), AT&T (T), Advanced Micro Devices (AMD) and Bristol-Myers Squibb (BMY). Company Calendar Last Earnings9/11/2024Today11/20/2024Next Earnings (Estimated)12/10/2024Fiscal Year End4/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CSBR CUSIPN/A CIK771856 Webwww.championsoncology.com Phone(201) 808-8400Fax410-369-0390Employees143Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+39.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,280,000.00 Net Margins-6.58% Pretax Margin-6.65% Return on EquityN/A Return on Assets-12.80% Debt Debt-to-Equity RatioN/A Current Ratio0.69 Quick Ratio0.69 Sales & Book Value Annual Sales$50.15 million Price / Sales1.17 Cash FlowN/A Price / Cash FlowN/A Book Value($0.14) per share Price / Book-30.71Miscellaneous Outstanding Shares13,590,000Free Float7,208,000Market Cap$58.44 million OptionableOptionable Beta0.50 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (NASDAQ:CSBR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Champions Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Champions Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
